Skip to main content

Table 1 Clinical characteristics of patients (PCa) and controls (BPH) in the Training, Validation1 and Validation 2 cohorts

From: A preliminary study of micro-RNAs as minimally invasive biomarkers for the diagnosis of prostate cancer patients

  Training cohort Validation cohort 1 Validation cohort 2
  All n = 70 BPH n = 37 52% PCa n = 33 48% p   All n = 90 BPH n = 45 50% PCa n = 45 50% p   All
n = 110
BPH
n = 65
59%
PCa
n = 45
41%
p
Age (Years) 67.15 ± 9 65.2 ± 10 69.1 ± 8 .314 Age (Years) 68 ± 8 66 ± 8 69.8 ± 7.8 .061 Age (Years) 69 ± 7.3 67.1 ± 7 70 ± 7.2 .154
PSA (ng/ml) 7.8 ± 5.5 5.6 ± 2 10 ± 5 .001 PSA (ng/ml) 8.78 ± 6 8.7 ± 4.8 8.8 ± 5.6 .769 PSA (ng/ml) 7 ± 5.8 7 ± 5.3 7.2 ± 6.7 .874
TRUS Volume (ml) 53.5 ± 29 68 ± 28 39 ± 12 .001 TRUS Volume (ml) 51.8 ± 28 55 ± 23 48 ± 21 .321 TRUS Volume (ml) 55 ± 27 61 45.5 ± 19 .053
   EG < 2
n = 14
42%
EG > 3
n = 19
45%
    EG < 2
n = 12
27%
EG > 3
n = 19
73%
    EG < 2
n = 28
62%
EG > 3
n = 17
38%
 
Age (Years)   69.8 ± 7.7 67 ± 8 .743 Age (Years)   68.5 ± 7.3 70 ± 8 .465 Age (Years)   69 ± 7 73 ± 7 .308
PSA (ng/ml) 10 ± 6.8 9.6 ± 4.5 .924 PSA (ng/ml) 5.8 ± 2 9.9 ± 6.2 .022 PSA (ng/ml) 6.5 ± 2.9 9.06 ± 7 .029
TRUS Volume (ml) 37 ± 12 40 ± 11 .487 TRUS Volume (ml) 48 ± 27 48 ± 18 .906 TRUS Volume (ml) 43.5 ± 19 54.5 ± 19 .664
  1. Abbreviations: BPH Benign Prostate Hyperplasia, PCa Prostate cancer, PSA Prostate Specific Antigen, TRUS transrectal ultrasound, EG Epstein group. Data are presented as median ± standard deviation